Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

Phase 4

Terminated

• Conditions: Coronary Disease; Myocardial Infarction

• Registration Number: NCT00320229
• Lead Sponsor: Azienda Sanitaria Ospedaliera

Brief Summary

The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications

Detailed Description

Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab bolus (group A) and to standard regimen (group B).

Study Timeline

• Study Start: 2004-12
• Study Completion: 2005-07
• Status Verified: 2006-01
• Study First Submitted: 2006-04-18
• Study First Submitted QC: 2006-05-01
• Study First Posted: 2006-05-03
• Last Update Submitted: 2006-05-15
• Last Update Posted: 2006-05-16

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

• presenting with unstable angina
• presenting with acute myocardial infarction
• eligibility for percutaneous coronary intervention

Exclusion Criteria

• presenting with cardiogenic shock

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Cardiologia 2 - Emodinamica - Ospedale Maggiore; 🇮🇹 Novara, Italy